Items Tagged ‘checkmate-238’

July 18th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in patients receiving Opdivo compared to Yervoy. There remains an unmet need for additional treatment options for individuals with stage III and resected stage IV high-risk melanoma […]

View full entry

Tags: adjuvant therapy, checkmate-238, checkpoint inhibitor, Melanoma, News, nivolumab, opdivo, PD-1, Precision Cancer Medicine